| Daniel Bryson Thornley, | |
|
1973 Miller Rd, Adrian, OR 97901-5088 | |
| (208) 919-4832 | |
| Not Available |
| Full Name | Daniel Bryson Thornley |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 3 Years |
| Location | 1973 Miller Rd, Adrian, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952988396 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | (* (Not Available)) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Asante Rogue Regional Medical Center | Medford, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Immediate Care, Llc | 7618876723 | 36 |
News Archive
One out of five adults suffers from chronic pain and half of all patients have been suffering for at least seven years (median). Patients usually go through an odyssey of examinations and treatments while long term relief becomes a hope rather than an expectation.
Group of scientists at Kaunas University of Technology, Lithuania are investigating the possibilities of using berry pomace to increase the safety of meat products and, probably, to mitigate their negative effects on human health.
A revolutionary new technology has been applied to reveal the inner workings of individual cancer cells - potentially identifying more effective treatment combinations for people with cancer.
Virginia Commonwealth University School of Medicine researchers have discovered a new role for the bioactive lipid messenger, sphingosine-1-phosphate, or S1P, that is abundant in our blood - a finding that could lead to a new generation of drugs to fight cancer and inflammatory disease.
AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Bryson Thornley, 1973 Miller Rd, Adrian, OR 97901-5088 Ph: (208) 919-4832 | Daniel Bryson Thornley, 1973 Miller Rd, Adrian, OR 97901-5088 Ph: (208) 919-4832 |
News Archive
One out of five adults suffers from chronic pain and half of all patients have been suffering for at least seven years (median). Patients usually go through an odyssey of examinations and treatments while long term relief becomes a hope rather than an expectation.
Group of scientists at Kaunas University of Technology, Lithuania are investigating the possibilities of using berry pomace to increase the safety of meat products and, probably, to mitigate their negative effects on human health.
A revolutionary new technology has been applied to reveal the inner workings of individual cancer cells - potentially identifying more effective treatment combinations for people with cancer.
Virginia Commonwealth University School of Medicine researchers have discovered a new role for the bioactive lipid messenger, sphingosine-1-phosphate, or S1P, that is abundant in our blood - a finding that could lead to a new generation of drugs to fight cancer and inflammatory disease.
AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).
› Verified 2 days ago